CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...
It is chasing after Vertex Pharma’s VX-548 ... of rinatabart sesutecan (Rina-S), a folate receptor-alpha targeted ADC, which is also in development for endometrial cancer.
At the front of its pipeline is ADCE-T02, a "highly differentiated" anti-tissue factor (TF) ADC that Adcendo licensed ... with applications across the pharma, food, and chemical sectors.
At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s ...
Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...
Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash.
March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings ... is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker ...
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
2d
TipRanks on MSNSutro Biopharma Prioritizes ADC Programs Amid Financial ShiftSutro Biopharma ( ($STRO) ) has released its Q4 earnings. Here is a breakdown of the information Sutro Biopharma presented to its investors. Sutro ...
Perform material- and labor-effective extrusion with Thermo Scientificâ„¢ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly The U.S. Food and Drug Administration's chief ...
4d
Pharmaceutical Technology on MSNWuXi XDC and AbTis collaborate on antibody-drug conjugatesThe partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results